Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2522-2532

  Park, Serk In ^a   Liao, Jinhui ^a   Berry, Janice E ^a   Li, Xin ^a   Koh, Amy J ^a   Michalski, Megan E ^a   Eber, Matthew R ^a   Soki, Fabiana N ^a   Sadler, David ^a   Sud, Ha ^b   Tisdelle, Sandra ^c   Daignault, Stephanie D ^a   Nemeth, Jeffrey A ^d   Snyder, Linda A ^d   Wronski, Thomas J ^c   Pienta, Kenneth J ^b   McCauley, Laurie K ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MODEL; CARCINOGENESIS; CELL COUNT; CELL EXPANSION; CELL LINEAGE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; HOST RESISTANCE; INFLAMMATION; INOCULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; BONE NEOPLASMS; CELL LINE, TUMOR; CHEMOKINE CCL2; CYCLOPHOSPHAMIDE; HUMANS; INTERLEUKIN-6; MALE; MICE; MYELOID CELLS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84861179255     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2928     Document Type: Article

References (38)

1. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer 2006;106: 1624-33.
2. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011;11:411-25.
3. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
4. Park SI, Soki FN, McCauley LK. Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron 2011;4: 237-46.
5. Seandel M, Butler J, Lyden D, Rafii S. A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization.Cancer Cell 2008;13: 181-3. (Pubitemid 351318378)
6. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21. (Pubitemid 39361441)
7. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008;13:193-205. (Pubitemid 351318369)
8. Ahn GO, Tseng D, Liao CH, Dorie MJ, Czechowicz A, Brown JM. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A; 107:8363-8.
9. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010;70: 5679-85.
10. Ahn GO, Brown JM. Influence of bone marrow-derived hematopoietic cells on the tumor response to radiotherapy: experimental models and clinical perspectives. Cell Cycle 2009;8:970-6.
11. Mizutani K, Sud S, McGregor NA, Martinovski G, Rice BT, Craig MJ, et al. The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia 2009;11:1235-42.
12. Mizutani K, Sud S, Pienta KJ. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts. J Cell Biochem 2009;106:563-9.
13. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010;102: 522-8.
14. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-9.
15. Abrams RA, Johnston-Early A, Kramer C, Minna JD, Cohen MH, Deisseroth AB. Amplification of circulating granulocyte-monocyte stem cell numbers following chemotherapy in patients with extensive small cell carcinoma of the lung. Cancer Res 1981;41:35-41. (Pubitemid 11218790)
16. Vollmer TL, Conley FK. Effect of cyclophosphamide on survival of mice and incidence of metastatic tumor following intravenous and intracardial inoculation of tumor cells. Cancer Res 1984;44:3902-6. (Pubitemid 14041613)
17. Carmel RJ, Brown JM. The effect of cyclophosphamide and other drugs on the incidence of pulmonary metastases in mice. Cancer Res 1977;37:145-51. (Pubitemid 8009289)
18. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia 2009;11:187-95.
19. Yamauchi K, Yang M, Hayashi K, Jiang P, Yamamoto N, Tsuchiya H, et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 2008;68:516-20. (Pubitemid 351380079)
20. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005;146:1727-36. (Pubitemid 40396881)
21. Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 2011;51:145-527.
22. Guldberg RE, Duvall CL, Peister A, Oest ME, Lin AS, Palmer AW, et al. imaging of tissue integration with porous biomaterials. Biomaterials 2008;29:3757-61.
23. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007; 67:9417-24. (Pubitemid 47535932)
24. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res 2009;69:1685-92.
25. Tsui P, Das A, Whitaker B, Tornetta M, Stowell N, Kesavan P, et al. Generation, characterization and biological activity of CCL2 (MCP-1/ JE) and CCL12 (MCP-5) specific antibodies. Hum Antibodies 2007;16: 117-25. (Pubitemid 351359901)
26. Bagley CM Jr, Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. Cancer Res 1973;33:226-33.
27. Kline I, Gang M, Tyrer DD, Mantel N, Venditti JM, Goldin A. Duration of drug levels in mice as indicated by residual antileukemic efficacy. Chemotherapy 1968;13:28-41.
28. Shirota T, Tavassoli M. Cyclophosphamide-induced alterations of bone marrow endothelium: implications in homing of marrow cells after transplantation. Exp Hematol 1991;19:369-73.
29. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76. (Pubitemid 36749215)
30. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457:102-6.
31. Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009;284:34342-54.
32. Chantrain CF, Feron O, Marbaix E, Declerck YA. Bone marrow micro-environment and tumor progression. Cancer Microenviron 2008;1: 23-35.
33. Man S, Zhang Y, Gao W, Yan L, Ma C. Cyclophosphamide promotes pulmonary metastasis on mouse lung adenocarcinoma. Clin Exp Metastasis 2008;25:855-64.
34. van Putten LM, Kram LK, van Dierendonck HH, Smink T, Fuzy M. Enhancement by drugs of metastatic lung nodule formation after intravenous tumour cell injection. Int J Cancer 1975;15:588-95.
35. Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006; 66:1664-74. (Pubitemid 43259951)
36. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177:2136-40. (Pubitemid 46726410)
37. McClatchey KD, editor. Clinical laboratory medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
38. Dai J, Lu Y, Yu C, Keller JM, Mizokami A, Zhang J, et al. Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors. Cancer Res 2010;70:5014-23.